Final results for the year ended 30 June 2026

ABINGDON HEALTH PLC – Final results for the year ended 30 June 2026

Abingdon Health plc (AIM:ABDX | OTCQB: ABDXF) executive chairman, Chris Hand, and CFO, Tom Hayes, presented the company’s FY2026 full-year results and its continued progress towards becoming an integrated partner for the development, manufacture, testing and regulatory approval of rapid diagnostic tests and medical technologies.

The discussion covered a year of 30% growth, with total revenue up 30% to £11.3m and contract development revenue up 56% to £5.0m. Gross margin improved to 47.1% (FY25: 44.3%), cash at 30th June stood at £2.9m, and the company moved into adjusted EBITDA profitability in the second half.

Growth was supported by a growing portfolio of multi-year customer contracts that provide greater revenue visibility. Abingdon Health continues to strengthen its end-to-end offering through three strategic pillars: Abingdon Diagnostics, Abingdon AI & MedTech, and Abingdon Analytical, which provides performance evaluation, laboratory testing and clinical research services.

Recent investment has expanded the company’s capabilities on both sides of the Atlantic, including a UKAS-accredited laboratory in Doncaster and established manufacturing at its Madison, Wisconsin facility to support growing demand from US customers. The group is also targeting opportunities in artificial intelligence, software as a medical device and emerging diagnostic technologies.

Looking ahead, the company is focused on delivering its current contracts and converting a strong pipeline of opportunities as it scales its integrated diagnostics and MedTech offering across the UK and US.